RecruitingNot ApplicableNCT06803771

Surveillance of Pancreatic Health After Diabetes Diagnosis

A Randomised Trial to Evaluate the cfDNA Pancreatic Cancer Test (Avantect) in the Early Detection of Pancreatic Cancer in Patients With Newly Diagnosed Diabetes Mellitus


Sponsor

University Hospital Southampton NHS Foundation Trust

Enrollment

15,000 participants

Start Date

May 21, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this interventional study is to evaluate if the novel diagnostic blood test, called Avantect can early detect pancreatic cancer in patients diagnosed with type 2 diabetes within the last 6 months. Participants will: * attend 3 study visits over 12 months time * provide a blood sample at each study visit * complete an anxiety questionnaire at each visit.


Eligibility

Min Age: 50 YearsMax Age: 84 Years

Inclusion Criteria5

  • years of age at the time of enrolment (within year of birth, not month of birth)
  • Haemoglobin A1c (HbA1c) ≥ 48 or 6.5% and/or confirmed type II DM diagnosed within the last 180 days (+20 days flexibility allowance)
  • Willing to provide up to 30 mL of blood for each study visit
  • Willing and eligible to undergo MRI scan (or CT scan if MRI is contraindicated)
  • Understands the study process and is willing to take part in the study and sign the informed consent form

Exclusion Criteria10

  • Prior type I or type II DM diagnosis \> 6 months
  • A history of pancreatic cancer, pancreatic neuroendocrine tumour (pNET) or Pancreatitis
  • Under investigation for pancreatic cancer / pancreatic cyst
  • Any known pancreatic surgery (not including ERCP), or other major surgery requiring anaesthesia within 3 months
  • Any invasive solid or haematological cancer in the past 3 years, including cancer recurrence after treatment in the last 3 years
  • Current chronic or acute oral or systemic steroid use within 3 months of initial HbA1c or diabetes diagnosis (estimate rather than accurate)
  • Blood transfusion within 1 month
  • Solid organ transplant recipient
  • Currently pregnant
  • Needing dialysis

Interventions

DEVICEAvantect Pancreatic Cancer Test

Avantect test


Locations(14)

Brockwood Medical Practice

Brockham, Surrey, United Kingdom

Integrated Care Partnership/ The Old Cottage Hospital

Epsom, Surrey, United Kingdom

Warlingham Green Medical Practice

Warlingham, Surrey, United Kingdom

Bournemouth Research Hub

Bournemouth, United Kingdom

Willesden Medical Centre

London, United Kingdom

South Westminster Centre

London, United Kingdom

The Cuckoo Lane Practice

London, United Kingdom

King's Mill Hospital (Sherwood Forest) Research Van

Nottingham, United Kingdom

Portsmouth Research Hub

Portsmouth, United Kingdom

Pembroke Centre (Hillingdon)

Ruislip, United Kingdom

Southampton Research Hub (Shirley Research Hub)

Southampton, United Kingdom

Moorgreen Hospital

Southampton, United Kingdom

Civic Centre

Uxbridge, United Kingdom

Weymouth Research Hub

Weymouth, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06803771


Related Trials